Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 14, Issue 1, Pages 109-126Publisher
SPRINGER
DOI: 10.1007/s11864-012-0222-4
Keywords
Prostate cancer; Novel; Treatments; Castration-resistant; Androgen receptor; Metastatic; PI3 kinase inhibitors; Androgen synthesis inhibitors; Immunotherapies; Epigenetic; Epithelial mesenchymal transition
Categories
Funding
- Dendreon
- Sanofi Aventis
- Janssen
- Pfizer
Ask authors/readers for more resources
In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available